Evaluation of Soluble ST2 in Patients Receiving Primary PCI With ST-elevation Myocardial Infarction

Using Soluble ST2 to Predict Clinical Outcomes in Patients Receiving Primary Percutaneous Coronary Intervention With ST-elevation Myocardial Infarction

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02830217

Enrollment

200

Registered

2016-07-12

Start date

2015-12-31

Completion date

2018-12-20

Last updated

2019-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Shock

Keywords

STEMI, primary PCI, sST2, prognosis

Brief summary

ST-elevation myocardial infarction (STEMI) is an urgent symptom associated with sudden myocardial ischemia and ST segment elevated in ECG. Primary percutaneous coronary intervention (PCI) re-open infarct artery efficiently for STEMI patients. However, patients are readmitted shortly after the primary PCI for several unfavorable clinical outcomes including thrombosis in stent, recurrence of myocardial infarction, stroke, and heart failure. This study is intended to test the predictive ability of a new biomarker soluble ST2 (sST2) in peripheral blood. Previous studies have shown that elevated sST2 is highly associated with unfavorable clinical outcomes of patients with ischemia heart diseases and heart failure. This study will further investigate the ability of sST2 to predict unfavorable outcomes for STEMI patients after primary PCI.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with first onset STEMI receive primary PCI according to 2013 ACCF/AHA guideline for management of STEMI

Exclusion criteria

* Patients with previous stroke, pneumonia, cirrhosis, autoimmune diseases or severe infection are excluded from this study.

Design outcomes

Primary

Measure	Time frame	Description
stent restenosis	one year after primary PCI	Evidence of stent restenosis of the patients receiving primary PCI, confirmed by coronary angiography when patients are readmitted due to the related symptoms.
recurrence of myocardial infarction	one year after primary PCI	Evidence of myocardial infarction of the patients receiving primary PCI, confirmed by coronary angiography or ECG when patients are readmitted due to the related symptoms.
heart failure	one year after primary PCI	Evidence of heart failure of the patients receiving primary PCI, confirmed by clinical diagnosis when patients are readmitted due to the related symptoms.
cardiac death	one year after primary PCI	Evidence of death due to the cardiac dysfunction of the patients receiving primary PCI.

Countries

China

Outcome results